Going Viral - Dr. Balram Bhargava (Details)
INDIA'S JOURNEY IN DEVELOPING COVAXIN
CHALLENGE FACED |
CONTEXT |
CHALLENGE DEFEATED |
Lack of health infrastructure |
|
|
Shortage of sufficient samples for ICMR and NIV to isolate and study
virus |
|
12 tourist samples arrived in New Delhi Genomic sequencing was conducted overnight |
Requirement of mass production of testing kits |
|
|
The key challenge to procuring components to develop kits |
|
|
Testing 1.3 billion people for infection |
By May 2020, India was performing 100.000 COVID tests/per day |
|
Logistic issues in conducting RT-PCR tests |
|
|
Making testing accessible to all Indians |
|
|
Testing stranded Indian pilgrims in Iran |
|
Small team from NIV flew to Tehran to conduct testing. Incredibly
patriotic! |
Speculation of Plasma therapy as a treatment modality |
Patients insisted in desperation as a form of treatment |
PLACID trial from April to June 2020 confirmed that convalescent
plasma had no effect on treatment. |
|
|
|
Vaccine development 1. Acquiring
Rhesus monkeys for testing 2. Protecting
the experimental animals from SARS before starting preclinical trials 3. Performing
large animals experiments in NIVs high security containment facility |
-
|
|
Comments
Post a Comment